Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma

International Journal of Cancer

Volumn 129, Issue 5, 2011, Pages 1096-1104

  Winder, Thomas ^a   Ning, Yan ^a   Yang, Dongyun ^a   Zhang, Wu ^a   Power, Derek G ^b   Bohanes, Pierre ^a   Gerger, Armin ^a   Wilson, Peter M ^a   Lurje, Georg ^a   Tang, Laura H ^b   Shah, Manish ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Molecular Biology and Genetics   (United States)

Author keywords

CD44; gastric adenocarcinoma; outcome; polymorphisms

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HERMES ANTIGEN; HYALURONIC ACID; IRINOTECAN; OSTEOPONTIN; OXALIPLATIN;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CD44 GENE; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GERM LINE; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TUMOR RECURRENCE; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 79959703558     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25787     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin, in press.
3. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y,. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). In ASCO 2009; J Clin Oncol 2009; 27 (suppl; abstr LBA4509): 18s.
4. Macdonald JS,. Treatment of localized gastric cancer. Semin Oncol 2004; 31: 566-73.
5. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS,. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-16. (Pubitemid 39425773)
6. Lauren P,. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
7. Keller G, Hofler H, Becker KF,. Molecular medicine of gastric adenocarcinomas. Expert Rev Mol Med 2005; 7: 1-13.
8. Ponta H, Sherman L, Herrlich PA,. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45. (Pubitemid 36077255)
9. Weber GF, Ashkar S, Glimcher MJ, Cantor H,. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12. (Pubitemid 26044470)
10. Lin YH, Yang-Yen HF,. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001; 276: 46024-30.
11. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC,. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 1997; 272: 27913-8. (Pubitemid 27473595)
12. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW,. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999; 43: 269-87. (Pubitemid 29368201)
13. Lesley J, English NM, Gal I, Mikecz K, Day AJ, Hyman R,. Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6. J Biol Chem 2002; 277: 26600-8. (Pubitemid 34967158)
14. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A,. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 1994; 126: 391-401. (Pubitemid 24226255)
15. Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM,. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 1996; 74: 342-51. (Pubitemid 26254561)
16. Naor D, Sionov RV, Ish-Shalom D,. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319. (Pubitemid 27197761)
17. Liu YJ, Yan PS, Li J, Jia JF,. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol 2005; 11: 6601-6. (Pubitemid 43072697)
18. Yoo CH, Noh SH, Kim H, Lee HY, Min JS,. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. J Surg Oncol 1999; 71: 22-8. (Pubitemid 29244906)
19. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC,. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-20.
20. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME,. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics 2009; 3: 128-42.
21. Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Muller TH, Wurl P, Bond GL,. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 2010; 70: 172-80.
22. Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M,. Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 2010; 30: 1263-72.
23. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, Omura M, Sekiguchi K, et al. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 69: 685-93. (Pubitemid 47418413)
24. Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One 2008; 3: e0001757.
25. Neuberger J, Altman DG, Christensen E, Tygstrup N, Williams R,. Use of a prognostic index in evaluation of liver transplantation for primary biliary cirrhosis. Transplantation 1986; 41: 713-6. (Pubitemid 16062684)
26. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh-Kermani A, Moaven O, Bahrani M,. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008; 14: 6376-81.
27. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK,. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009; 59: 241-6.
28. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI,. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-4. (Pubitemid 23004805)
29. Skelton TP, Zeng C, Nocks A, Stamenkovic I,. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol 1998; 140: 431-46. (Pubitemid 28078406)
30. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC,. Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res 2003; 63: 887-92. (Pubitemid 36231993)
31. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P,. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24. (Pubitemid 121001209)
32. Heider KH, Dammrich J, Skroch-Angel P, Muller-Hermelink HK, Vollmers HP, Herrlich P, Ponta H,. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53: 4197-203. (Pubitemid 24146766)
33. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zoller M,. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 2009; 7: 168-79.
34. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST,. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-6. (Pubitemid 23326158)
35. Pagani F, Baralle FE,. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004; 5: 389-96. (Pubitemid 38529410)
36. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65: 1213-22. (Pubitemid 40270146)
37. Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA,. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9: 3961S-72S. (Pubitemid 37169203)
38. Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Borjesson PK, Huijgens PC, Snow GB, van Dongen GA,. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 2002; 8: 3401-6. (Pubitemid 35340714)
39. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F, Poupon MF,. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009; 100: 918-22.
40. Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn HP, Sohn C, Schneeweiss A,. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007; 18: 477-85. (Pubitemid 46712412)
41. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA,. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12: 6064-72. (Pubitemid 44703770)